Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Statement re. Media Comment

15 Jun 2021 10:49

RNS Number : 9486B
Omega Diagnostics Group PLC
15 June 2021
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Statement re. Media Comment

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the recent media comment that Mologic Ltd have requested for Porton Down to evaluate their lateral flow antigen test with an independent party observing.

 

This process has no implications on the UK Government manufacturing contract that Omega has in place with the Department of Health and Social Care ("DHSC"). Under that contract Omega will provide manufacturing capacity for COVID-19 lateral flow antigen tests utilising the key pieces of manufacturing equipment loaned by the UK Government for that purpose and Omega will manufacture whichever test is approved for use by the DHSC. As clarified on 7 June 2021 the ability to supply tests that are produced within the UK remains a key priority for the DHSC and to that end the DHSC have facilitated initial commercial discussions between Omega and a number of companies with lateral flow antigen tests to potentially provide UK manufacturing services.

 

As already announced on 8 June 2021 Omega is in the process of seeking CE marking of its VISITECT® COVID-19 Antigen test, as a self-test. Final preparations for a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for this test is also underway.

 

Recently published study data confirms that Mologic's lateral flow antigen test, being commercialised by Omega as the VISITECT® COVID-19 Antigen test, demonstrates high diagnostic accuracy (specificity and sensitivity) fulfilling WHO target accuracy with a high sensitivity (93.2%-98.4%) detecting individuals with high viral load infections (Ct

 

Further details of the study and the FIND report can be seen using the links below:

https://www.londonstockexchange.com/news-article/ODX/positive-data-for-covid-19-antigen-test/14998113

https://www.londonstockexchange.com/news-article/ODX/positive-data-for-mologic-covid-19-antigen-test/14963499

 

 Contacts: 

 

Omega Diagnostics Group PLC

www.omegadiagnostics.com

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director

 

 

 

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

 

Alice Lane (ECM)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SPCEANKSFLKFEEA
Date   Source Headline
16th Sep 202211:13 amRNSPurchase of Shares by Directors
13th Sep 20227:00 amRNSInvestor presentation and Confirmation of AGM
12th Sep 20227:00 amRNSFinal Results
2nd Sep 202210:15 amRNSHolding(s) in Company
31st Aug 20227:00 amRNSChange of preliminary results date
12th Aug 20227:00 amRNSChange of preliminary results date
8th Aug 20227:00 amRNSConfirmation of Preliminary Results
5th Aug 202212:09 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSCompletion of Sale of the CD4 Business
11th Jul 20227:00 amRNSPayment received
4th Jul 20227:00 amRNSHeads of Terms agreed for Sale of CD4 Business
23rd Jun 20223:13 pmRNSHolding(s) in Company
10th Jun 20227:00 amRNSGrant of share incentive awards
8th Jun 20221:47 pmRNSPDMR/Director Dealing
6th Jun 20222:29 pmRNSResult of General Meeting and Total Voting Rights
1st Jun 20227:00 amRNSResult of Open Offer
13th May 202210:05 amRNSPosting of Circular and Notice of General Meeting
11th May 20223:28 pmRNSHolding(s) in Company
6th May 20227:01 amRNSInvestor presentation
6th May 20227:00 amRNSPlacing, Subscription and Open Offer
7th Apr 20227:00 amRNSTrading Update
11th Mar 20227:00 amRNSUpdate on validation under CTDA legislation
8th Mar 20224:41 pmRNSSecond Price Monitoring Extn
8th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20224:41 pmRNSSecond Price Monitoring Extn
7th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20223:40 pmRNSResult of General Meeting
7th Mar 202211:03 amRNSConfirmation of Sale of Alva business
1st Mar 20227:00 amRNSResult of Open Offer
18th Feb 20227:00 amRNSInvestor Meeting
14th Feb 20222:06 pmRNSSecond Price Monitoring Extn
14th Feb 20222:01 pmRNSPrice Monitoring Extension
11th Feb 202211:05 amRNSSecond Price Monitoring Extn
11th Feb 202211:00 amRNSPrice Monitoring Extension
11th Feb 20227:01 amRNSFundraising to raise gross proceeds of up to £7m
11th Feb 20227:00 amRNSSale of Alva manufacturing business
10th Feb 20222:06 pmRNSSecond Price Monitoring Extn
10th Feb 20222:00 pmRNSPrice Monitoring Extension
10th Feb 20221:33 pmRNSSpeculation regarding a potential fundraise
8th Feb 20224:41 pmRNSSecond Price Monitoring Extn
8th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSCE-Mark for self-test for VISITECT® COVID-19 test
2nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20224:36 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSSpeculation regarding a potential fundraise
19th Jan 20227:00 amRNSDirectorate Change
10th Jan 20223:20 pmRNSConfirmation of detection of Omicron variant
4th Jan 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.